Target (CBDY) Net Income towards Common Stockholders (2013 - 2026)
Target (CBDY) reported Net Income towards Common Stockholders of -$550356.0 for Q1 2026, down 408.59% year-over-year from $178347.8 in Q1 2025, and little changed quarter-over-quarter from -$552307.0 in Q4 2025.
Target (CBDY) Net Income towards Common Stockholders (2013 - 2026) Analysis & Trends
Target (CBDY) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$550356.0 in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$550356.0, down 408.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.8 million (down 834.06% YoY), and the FY2025 annual result was -$1.4 million, down 947.13% from the prior year.
- Net Income towards Common Stockholders was little changed at -$550356.0 in Q1 2026 per CBDY's latest filing, from -$552307.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $963816.0 in Q2 2023 and troughed at -$3.9 million in Q4 2022.
- A 5-year average of -$401826.6 and a median of -$286149.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 279.32% in 2023 and fell as far as 5916.71% in 2023.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.9 million in 2022, then surged by 95.28% to -$184965.0 in 2023, then soared by 216.76% to $215958.0 in 2024, then tumbled by 355.75% to -$552307.0 in 2025, then climbed by 0.35% to -$550356.0 in 2026.
- Business Quant data shows CBDY's Net Income towards Common Stockholders at -$550356.0 in Q1 2026, -$552307.0 in Q4 2025, and -$479392.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Target | - | - | 191,787.00 | -550,356.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -550,356.00 |
| Dec 31, 2025 | -552,307.00 |
| Sep 30, 2025 | -479,392.00 |
| Jun 30, 2025 | -219,770.00 |
| Mar 31, 2025 | -108,213.00 |
| Dec 31, 2024 | 215,958.00 |
| Sep 30, 2024 | -528,950.00 |
| Jun 30, 2024 | 666,664.00 |
| Mar 31, 2024 | -193,168.00 |
| Dec 31, 2023 | -184,965.00 |
| Sep 30, 2023 | -356,812.00 |
| Jun 30, 2023 | 963,816.00 |
| Mar 31, 2023 | -745,709.00 |
| Dec 31, 2022 | -3.92 Mn |
| Sep 30, 2022 | -286,149.00 |
| Jun 30, 2022 | -537,489.83 |
| Mar 31, 2022 | -12,393.97 |
| Dec 31, 2021 | -392,386.41 |
| Sep 30, 2021 | -66,325.23 |
| Jun 30, 2021 | 827,015.00 |